Skip to main content

Compare Stocks

Date Range: 

 Checkpoint TherapeuticsMedicenna TherapeuticsSierra OncologyLannettImmutep
SymbolNASDAQ:CKPTNASDAQ:MDNANASDAQ:SRRANYSE:LCINASDAQ:IMMP
Price Information
Current Price$2.38$3.41$17.60$4.56$3.54
52 Week RangeBuyBuyBuyHoldBuy
MarketRank™
Overall Score1.20.71.82.11.3
Analysis Score3.53.53.53.03.5
Community Score2.60.02.62.62.9
Dividend Score0.00.00.00.00.0
Ownership Score0.00.02.52.50.0
Earnings & Valuation Score0.00.00.62.50.0
Analyst Ratings
Consensus RecommendationBuyBuyBuyHoldBuy
Consensus Price Target$17.67$10.00$28.00$8.50$7.00
% Upside from Price Target642.30% upside193.26% upside59.09% upside86.40% upside97.74% upside
Trade Information
Market Cap$179.01 million$182.60 million$217.36 million$188.99 million$229.65 million
Beta1.661.391.311.312.23
Average Volume1,288,895206,34731,304583,5212,077,797
Sales & Book Value
Annual Revenue$1.71 millionN/AN/A$545.74 million$4.92 million
Price / Sales104.68N/AN/A0.3546.68
CashflowN/AN/AN/A$1.71 per shareN/A
Price / CashN/AN/AN/A2.66N/A
Book Value$0.34 per share$0.77 per share$8.93 per share$7.51 per share$0.57 per share
Price / Book7.00N/AN/A0.616.21
Profitability
Net Income$-24,710,000.00$-6,220,000.00$-88,280,000.00$-33,370,000.00$-9,040,000.00
EPS($0.70)($0.19)($19.52)$1.07N/A
Trailing P/E RatioN/AN/AN/AN/A0.00
Forward P/E RatioN/AN/AN/A4.90
P/E GrowthN/AN/AN/AN/AN/A
Net Margins-2,032.05%N/AN/A-5.09%N/A
Return on Equity (ROE)-100.54%-40.19%-55.08%12.62%N/A
Return on Assets (ROA)-75.09%-37.66%-45.75%3.39%N/A
Dividend
Annual PayoutN/AN/AN/AN/AN/A
Dividend YieldN/AN/AN/AN/AN/A
Three-Year Dividend GrowthN/AN/AN/AN/AN/A
Payout RatioN/AN/AN/AN/AN/A
Years of Consecutive Dividend GrowthN/AN/AN/AN/AN/A
Debt
Debt-to-Equity RatioN/AN/AN/A1.96%0.26%
Current Ratio6.64%26.75%14.99%2.02%9.26%
Quick Ratio6.64%26.75%15.00%1.30%9.26%
Ownership Information
Institutional Ownership Percentage18.75%3.90%62.32%86.12%0.16%
Insider Ownership Percentage7.80%N/A67.68%13.63%N/A
Miscellaneous
Employees10769954N/A
Shares Outstanding75.21 million53.55 million12.35 million41.45 million64.87 million
Next Earnings Date8/4/2021 (Estimated)5/21/2021 (Estimated)8/5/2021 (Estimated)8/25/2021 (Estimated)N/A
OptionableNot OptionableNot OptionableOptionableOptionableNot Optionable
SourceHeadline
Keep on Avoiding Nio Stock, as Signs Point to Even Lower Prices - Report DoorKeep on Avoiding Nio Stock, as Signs Point to Even Lower Prices - Report Door
reportdoor.com - May 16 at 12:32 PM
Immune Checkpoint Inhibitors Market is Likely to Increase at a Significantly High CAGR during Forecast Period 2027 – Clark County Blog - Clark County BlogImmune Checkpoint Inhibitors Market is Likely to Increase at a Significantly High CAGR during Forecast Period 2027 – Clark County Blog - Clark County Blog
clarkcountyblog.com - May 13 at 3:58 PM
Latest Insights On Immune Checkpoint Inhibitors Industry. Major Players included in the report are Bristol Myer Squibb, AstraZeneca, Merck & Co., Roche / Genentech, Incyte Corporation, etc. – Clark County Blog - Clark County BlogLatest Insights On Immune Checkpoint Inhibitors Industry. Major Players included in the report are Bristol Myer Squibb, AstraZeneca, Merck & Co., Roche / Genentech, Incyte Corporation, etc. – Clark County Blog - Clark County Blog
clarkcountyblog.com - May 13 at 10:57 AM
Global Parkinsons Disease Market Current Scenario Trends, Comprehensive Analysis and Regional Forecast to 2028||GlaxoSmithKline Plc, Acorda Therapeutics, Inc, Amneal Pharmaceuticals LLC , Imugene Limited, Immutep – The Manomet Current - The Manomet CurrentGlobal Parkinson's Disease Market Current Scenario Trends, Comprehensive Analysis and Regional Forecast to 2028||GlaxoSmithKline Plc, Acorda Therapeutics, Inc, Amneal Pharmaceuticals LLC , Imugene Limited, Immutep – The Manomet Current - The Manomet Current
manometcurrent.com - May 12 at 6:34 PM
Immutep Operational Update - GlobeNewswireImmutep Operational Update - GlobeNewswire
globenewswire.com - May 7 at 9:06 AM
Immutep (NASDAQ:IMMP) Stock Passes Below 50-Day Moving Average of $3.23Immutep (NASDAQ:IMMP) Stock Passes Below 50-Day Moving Average of $3.23
americanbankingnews.com - May 7 at 3:40 AM
Immutep - Operational Update - Finance News NetworkImmutep - Operational Update - Finance News Network
finnewsnetwork.com.au - May 6 at 11:04 PM
Bristol Myers Squibbs Latest Data Could Help the Pharma Leapfrog Rival Merck - NasdaqBristol Myers Squibb's Latest Data Could Help the Pharma Leapfrog Rival Merck - Nasdaq
nasdaq.com - May 3 at 7:46 AM
Immutep : Corporate Connect - Efti a highly sort after compound for mono & combo Cancer treatment - Marketscreener.comImmutep : Corporate Connect - Efti a highly sort after compound for mono & combo Cancer treatment - Marketscreener.com
marketscreener.com - April 30 at 10:32 AM
BMSs Cancer Trial Highlights Potential for Immune Checkpoint Inhibitors - Labiotech.euBMS's Cancer Trial Highlights Potential for Immune Checkpoint Inhibitors - Labiotech.eu
labiotech.eu - April 29 at 8:01 AM
Immutep (ASX:IMM) primed to present data at ASCO Annual Meeting - The Market HeraldImmutep (ASX:IMM) primed to present data at ASCO Annual Meeting - The Market Herald
themarketherald.com.au - April 28 at 8:14 PM
Immutep To Announce New TACTI-002 and INSIGHT-004 Data in Poster Presentations and Discussion at the ASCO 2021 Annual Meeting - GlobeNewswireImmutep To Announce New TACTI-002 and INSIGHT-004 Data in Poster Presentations and Discussion at the ASCO 2021 Annual Meeting - GlobeNewswire
globenewswire.com - April 28 at 3:14 PM
Short Interest in Immutep Limited (NASDAQ:IMMP) Decreases By 64.7%Short Interest in Immutep Limited (NASDAQ:IMMP) Decreases By 64.7%
americanbankingnews.com - April 28 at 5:46 AM
What Type Of Shareholders Own The Most Number of Immutep Limited (ASX:IMM) Shares? - Yahoo FinanceWhat Type Of Shareholders Own The Most Number of Immutep Limited (ASX:IMM) Shares? - Yahoo Finance
finance.yahoo.com - April 26 at 1:43 AM
Immutep Receives A$1,155,055 R&D Tax Incentive - Yahoo FinanceImmutep Receives A$1,155,055 R&D Tax Incentive - Yahoo Finance
finance.yahoo.com - April 16 at 8:33 AM
Immutep Receives A$1,155,055 R&D Tax IncentiveImmutep Receives A$1,155,055 R&D Tax Incentive
finance.yahoo.com - April 16 at 8:33 AM
Immutep Investor Update - Finance News NetworkImmutep Investor Update - Finance News Network
finnewsnetwork.com.au - April 14 at 4:51 AM
Why Prima is Creating DTC Solutions for StressWhy Prima is Creating DTC Solutions for Stress
finance.yahoo.com - April 12 at 2:01 PM
Immutep ADS Representing 10 Ord Shs (IMMP) is down 6.78% Friday In Premarket Trading - InvestorsObserverImmutep ADS Representing 10 Ord Shs (IMMP) is down 6.78% Friday In Premarket Trading - InvestorsObserver
investorsobserver.com - April 9 at 8:48 AM
IMMP Stock: The Big Patent News Boosting Immutep Today - InvestorPlaceIMMP Stock: The Big Patent News Boosting Immutep Today - InvestorPlace
investorplace.com - April 9 at 12:07 AM
Immutep Limited (IMMP) Stock Rises After FDA Designation - InvestorsObserverImmutep Limited (IMMP) Stock Rises After FDA Designation - InvestorsObserver
investorsobserver.com - April 9 at 12:07 AM
Immutep jumps 13% after getting fast-track status for its drug to treat head and neck cancer - Markets InsiderImmutep jumps 13% after getting fast-track status for its drug to treat head and neck cancer - Markets Insider
markets.businessinsider.com - April 9 at 12:07 AM
Why Immutep Limited Stock Popped Today - The Motley FoolWhy Immutep Limited Stock Popped Today - The Motley Fool
fool.com - April 9 at 12:07 AM
Netflix Inks Multi-Year Deal With Sony Pictures - NasdaqNetflix Inks Multi-Year Deal With Sony Pictures - Nasdaq
nasdaq.com - April 8 at 7:06 PM
Why Immutep Limited Stock Popped TodayWhy Immutep Limited Stock Popped Today
fool.com - April 8 at 5:31 PM
DateCompanyBrokerageAction
2/1/2021Checkpoint TherapeuticsCantor FitzgeraldReiterated Rating
9/29/2020Checkpoint TherapeuticsHC WainwrightBoost Price Target
7/15/2020Checkpoint TherapeuticsLADENBURG THALM/SH SHReiterated Rating
12/27/2019Checkpoint TherapeuticsLake Street CapitalReiterated Rating
12/17/2020Medicenna TherapeuticsOppenheimerInitiated Coverage
8/24/2020Medicenna TherapeuticsBrookline Capital ManagementReiterated Rating
8/24/2020Medicenna TherapeuticsBloom BurtonReiterated Rating
11/6/2020Sierra OncologyLifesci CapitalReiterated Rating
2/28/2019Sierra OncologyWedbushReiterated Rating
11/3/2020LannettRaymond JamesReiterated Rating
8/27/2020LannettRoth CapitalBoost Price Target
8/27/2020LannettBMO Capital MarketsReiterated Rating
9/18/2019LannettSunTrust BanksBoost Price Target
8/20/2018LannettCraig HallumDowngrade
1/26/2021ImmutepAlliance Global PartnersBoost Price Target
12/14/2020ImmutepMaxim Group
9/28/2018ImmutepB. RileyInitiated Coverage
(Data available from 5/16/2018 forward. View 10+ years of historical ratings with our analyst ratings screener.)
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.